3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
40
Neoplasms
4
Triple Negative Breast Neoplasms
3
Obesity
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Insulin Resistance
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Breast Cancer Female
2
Brain Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sleep Wake Disorders
1
Sezary Syndrome
1
Rectal Neoplasms
1
Racism
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Interventions
Trastuzumab
33
pertuzumab
18
Docetaxel
16
pyrotinib
15
Paclitaxel
7
Capecitabine
6
tucatinib
5
Carboplatin
5
Ado-Trastuzumab Emtansine
4
trastuzumab deruxtecan
3
neratinib
3
atezolizumab
2
Protons
2
Neoadjuvant Therapy
2
Fulvestrant
2
pegfilgrastim
1
palbociclib
1
margetuximab
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
envafolimab
1
dalpiciclib
1
Taxoids
1
Metformin
1
Leuprolide
1
Letrozole
1
Isovaleryl-CoA Dehydrogenase
1
Injections
1
Hospital Information Systems
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-positive Breast Cancer
×
Metformin
×
Breast
×
Clear all
NCT03238495
2021-12-07
HERMET
University of Kansas Medical Center
Phase 2
Unknown
100 enrolled